European EMA Approves Alvotech (ALVO) and STADA's Adalimumab Biosimilar 'Libmyris'
A New Challenger in the High-Concentration Adalimumab Market
The European Medicines Agency (EMA) has approved 'Libmyris,' an adalimumab biosimilar developed by Alvotech (ALVO) and commercialized by STADA. This drug is a high-concentration (100mg/mL) formulation of AbbVie's blockbuster drug, Humira, and works by inhibiting tumor necrosis factor-alpha (TNF-Ξ±), which causes autoimmune diseases. This approval grants STADA the regulatory authority to distribute and sell Libmyris throughout the European Union (EU). This is highly significant as it provides patients with an affordable treatment alternative that offers efficacy comparable to the original drug.
The First Success of the Two Companies' Strategic Partnership
The European approval of Libmyris was made possible by the strategic partnership between Alvotech and STADA, which was established in November 2019. Under the terms of the agreement, Alvotech is responsible for the development and manufacturing of a pipeline of seven biosimilars, including Libmyris, while STADA has secured exclusive commercialization rights and is responsible for the European distribution network. This approval demonstrates that the development capabilities and distribution synergies of the two companies have successfully passed the rigorous scientific review by regulatory authorities. In the future, the two companies plan to resolve patent disputes with the original manufacturer and remove obstacles to market entry.
Pressuring Prices in the 6.3 Billion Euro European Market
As of 2025, the European adalimumab market is estimated at approximately 6.35 billion USD, and fierce price competition has continued annually since the introduction of biosimilars. Most European health authorities adopt a centralized tender system that favors cost-competitive drugs, creating a favorable environment for the penetration of affordable biosimilars. The full-scale market entry of Libmyris is expected to serve as a catalyst for lowering the average price of anti-TNF therapies in Europe. This will reduce the financial burden of drug costs on national budgets and allow more patients to benefit from expensive biologics.
Fierce Competition in the High-Concentration Formulation Market
Currently, the European adalimumab market is dominated by high-concentration and citrate-free formulations, which improve patient convenience and reduce pain. As a result, Libmyris will face direct competition from strong competitors that have already established a presence in the market, such as Celltrion's Yuflyma and Sandoz's Hyrimoz. The success of STADA's strong local hospital marketing and sales network in tender competitions will be a key factor in securing market share in the future. We are also closely monitoring their efforts to increase market share by overcoming the defense strategies of the original drug.
This EMA approval signifies the availability of a new biosimilar supply in the approximately 6.35 billion USD European adalimumab market, offering enhanced price competitiveness with its high-concentration formulation. In the short term, Alvotech's global partner, STADA, will leverage its exclusive commercialization rights in Europe to participate in national centralized tenders, leading to intense competition for market share with Celltrion's Yuflyma and the original Humira. In the medium to long term, a smooth European market launch and increased sales volume based on patent agreements with the original manufacturer, AbbVie, will directly contribute to increased royalty revenue for Alvotech, accelerating the company's path to profitability. In particular, the high biological similarity and safety demonstrated in Phase 3 clinical trials, combined with the high-concentration, citrate-free formulation that reduces injection pain for patients, will be used as a key negotiating advantage in the European national tender market.
Source: EMA (ema)